Tech Company Financing Transactions
Tallac Therapeutics Funding Round
On 8/3/2023, Tallac Therapeutics secured $15 million in funding from Horizon Technology Finance.
Transaction Overview
Company Name
Announced On
8/3/2023
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Undisclosed
Investors
Horizon Technology Finance (Lead Investor)
Proceeds Purpose
The company will use the loan proceeds for general growth and working capital purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
866 Malcolm Rd. 100
Burlingame, CA 94010
USA
Burlingame, CA 94010
USA
Phone
Website
Email Address
Overview
Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Several TRAAC molecules are in various stages of discovery and preclinical development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hong Wan
VP - Bus. Development
Janet Sim
VP - Finance
Emma Abellana
Browse more venture capital transactions:
Prev: 8/3/2023: X4 Pharmaceuticals venture capital transaction
Next: 8/3/2023: Tenstorrent venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs